Trials / Completed
CompletedNCT00297661
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization: SIRTAX Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,012 (planned)
- Sponsor
- University of Bern · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Context: Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. It is unclear whether there are differences in safety and efficacy between the two types of drug-eluting stents. Objective: To determine differences in safety and efficacy between sirolimus and paclitaxel eluting stents.
Detailed description
Design: Randomized controlled, observer-blind trial comparing sirolimus-eluting stents with paclitaxel-eluting stents Patients: 1012 patients undergoing percutaneous coronary intervention. The two groups had similar baseline clinical and angiographic characteristics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Sirolimus-eluting stent | |
| DEVICE | Paclitaxel-eluting stent |
Timeline
- Start date
- 2003-04-01
- First posted
- 2006-02-28
- Last updated
- 2006-10-20
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00297661. Inclusion in this directory is not an endorsement.